Exelixis, Inc. (NASDAQ:EXEL) Shares Bought by Federated Hermes Inc.

Federated Hermes Inc. raised its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 82.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 408,932 shares of the biotechnology company's stock after purchasing an additional 185,389 shares during the period. Federated Hermes Inc. owned 0.14% of Exelixis worth $13,637,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. MassMutual Private Wealth & Trust FSB boosted its stake in Exelixis by 18.1% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company's stock worth $63,000 after buying an additional 290 shares in the last quarter. Steward Partners Investment Advisory LLC grew its stake in shares of Exelixis by 4.9% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company's stock valued at $235,000 after buying an additional 330 shares during the last quarter. Oregon Public Employees Retirement Fund increased its stake in Exelixis by 0.6% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 58,159 shares of the biotechnology company's stock worth $1,937,000 after purchasing an additional 354 shares during the period. Principal Securities Inc. boosted its position in Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock valued at $32,000 after buying an additional 373 shares during the period. Finally, V Square Quantitative Management LLC boosted its stake in shares of Exelixis by 37.3% during the 4th quarter. V Square Quantitative Management LLC now owns 1,563 shares of the biotechnology company's stock valued at $52,000 after purchasing an additional 425 shares in the last quarter. Institutional investors own 85.27% of the company's stock.

Remove Ads

Exelixis Stock Performance

Shares of EXEL traded up $0.46 during mid-day trading on Tuesday, hitting $36.20. 717,687 shares of the stock were exchanged, compared to its average volume of 2,670,859. The firm has a 50-day moving average of $36.21 and a two-hundred day moving average of $34.08. Exelixis, Inc. has a 52-week low of $20.14 and a 52-week high of $40.02. The company has a market cap of $10.13 billion, a PE ratio of 20.45, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, sell-side analysts predict that Exelixis, Inc. will post 2.04 EPS for the current year.

Insider Buying and Selling

In other Exelixis news, CFO Christopher J. Senner sold 29,314 shares of the company's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $36.14, for a total transaction of $1,059,407.96. Following the completion of the sale, the chief financial officer now owns 779,607 shares in the company, valued at $28,174,996.98. This represents a 3.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mary C. Beckerle sold 12,210 shares of Exelixis stock in a transaction on Friday, February 14th. The shares were sold at an average price of $34.88, for a total value of $425,884.80. Following the completion of the transaction, the director now owns 30,406 shares in the company, valued at $1,060,561.28. This represents a 28.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 140,343 shares of company stock valued at $5,177,234 over the last quarter. 2.85% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

EXEL has been the subject of several recent research reports. Stephens reissued an "equal weight" rating and set a $29.00 price objective on shares of Exelixis in a research report on Wednesday, February 12th. Barclays upped their price target on Exelixis from $25.00 to $29.00 and gave the stock an "equal weight" rating in a research note on Thursday, February 13th. JMP Securities restated a "market outperform" rating and set a $41.00 price objective on shares of Exelixis in a research note on Thursday, January 23rd. Brookline Capital Management initiated coverage on shares of Exelixis in a research note on Monday, December 23rd. They issued a "buy" rating on the stock. Finally, Bank of America lowered shares of Exelixis from a "buy" rating to a "neutral" rating and boosted their price objective for the stock from $35.00 to $39.00 in a report on Tuesday, December 17th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $37.59.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.